Age- and gender-specific incidence rates of renal replacement therapy in Japan: an international comparison by Minako Wakasugi et al.
Wakasugi et al. Renal Replacement Therapy  (2016) 2:5 
DOI 10.1186/s41100-016-0017-3RESEARCH Open AccessAge- and gender-specific incidence rates of
renal replacement therapy in Japan: an
international comparison
Minako Wakasugi1,2*, Junichiro James Kazama3 and Ichiei Narita2Abstract
Background: Japan has relatively low incidence rates of renal replacement therapy (RRT) for end-stage kidney
disease (ESKD) among those aged 0–19 years, but relatively high rates for the older age band. On the other hand,
Australia has relatively high rates among those aged 0–19 years, but relatively low rates for the older age band.
Thus, an international comparison between Japan and Australia would be informative. This study aimed to compare
age- and gender-specific incidence rates of RRT in Japan with the total incidence of ESKD in Australia, which
includes both those who start RRT and those who died of ESKD without RRT, in order to better understand the
burden of ESKD independently of differences in the acceptance rate of RRT. We also compared incidence rates in
Japan with published data from two major registries, the United States Renal Data System (USRDS) and the
European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).
Methods: Data on numbers of patients who initiated RRT in Japan were extracted from data published by the
Japanese Society of Dialysis Therapy (JSDT) Registry in 2003–2007 and 2011. Age- and gender-specific incidence
rates were calculated by dividing the number of incident patients for each age-gender category by the total
number of people in the corresponding population. Incidence in other countries was extracted from a published
paper in Australia, tables in the USRDS annual report 2011, and the ERA-EDTA annual report 2011.
Results: Among males aged 50 to 69 years, incidence rates of RRT in Japan were about two times the total
incidence of ESKD in Australia. Compared with the incidence rates of RRT reported by the USRDS and the
ERA-EDTA, Japanese males have similar or substantially higher rates, respectively.
Conclusions: Japan has a higher incidence of RRT among middle- and older-aged populations compared to the
total incidence rates of ESKD in Australia. This higher incidence in Japan cannot be explained by differences in the
acceptance rate for RRT since data from Australia included both treated and untreated ESKD. A strategy that targets
middle- and older-aged males will be necessary to decrease the incidence of RRT in Japan.
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The incidence of end-stage kidney disease (ESKD) differs
substantially between countries. According to information
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by 362 in the USA, 361 in Taiwan (2010), and 295 in Japan
[1]. However, these rates were not adjusted by age and
gender. Since the risk of ESKD differs by age and gender,
population demographics would affect the rates.
When considered by age band, some countries have
incidence rates of ESKD which are high in some age
bands and low in others [2]. Japan has relatively low
incidence rates of reported ESKD among those aged 0–
19 years, but relatively high rates for the older age band.
On the other hand, Australia has relatively high incidencecle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Wakasugi et al. Renal Replacement Therapy  (2016) 2:5 Page 2 of 7rates of reported ESKD among those aged 0–19 years, but
relatively low rates for the older age band [2]. These
findings suggest that an international comparison of
age- and gender-specific incidence rates between Japan
and Australia would be informative and drive further
research.
Recently, the total incidence of ESKD in Australia,
which includes both those who start renal replacement
therapy (RRT) and those who die of ESKD without RRT,
has been estimated [3]. Unfortunately, no data are avail-
able on the total incidence of adult ESKD in Japan.
However, it would be more informative to compare the
incidence of RRT in Japan with the total incidence of
ESKD in Australia, rather than the reported incidence
rates of ESKD (which include only those who start RRT),
in order to better understand the burden of ESKD inde-
pendently of differences in the acceptance rate of RRT.
This study aimed to compare age- and gender-specific
incidence rates of RRT in Japan with the total incidence of
ESKD in Australia. We also compared incidence rates in
Japan with published data from two major registries, the
USRDS and the European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA).
Methods
Data source
Data on numbers of patients who initiated RRT in Japan
were extracted from data published by the Japanese So-
ciety of Dialysis Therapy (JSDT) Registry in 2003–2007
[4–8] and 2011 [9]. Data collection methods of the JSDT
Registry have been described elsewhere [9]. In brief, the
JSDT Registry collects annual data by sending question-
naires to all dialysis facilities in Japan. Response rates
were 99.12 % in 2003 [4], 98.73 % in 2004 [5], 98.87 % in
2005 [6], 98.37 % in 2006 [7], 98.88 % in 2007 [8], and
99.0 % in 2011 [9]. It is important to note that only pa-
tients who underwent dialysis treatment were included
in the JSDT Registry, as data were unavailable for adult
patients who did not initiate dialysis or who received a
preemptive kidney transplant. Although the number of
preemptive kidney transplant patients is still small
among the adult Japanese population [10], there has
been a marked increase in the use of preemptive kidney
transplantation as the initial treatment modality for
paediatric RRT [11]. Thus, we also extracted data on in-
cident paediatric ESKD patients in Japan from survey
data published by the Japanese Society for Paediatric Ne-
phropathy (JSPN) in 2006–2011 [11], which included
patients who did not initiate RRT or who received pre-
emptive kidney transplants.
Population data in 2003–2007 and 2011 were ex-
tracted from the national census [12, 13]. Data on age-
and gender-specific total incidence of ESKD in Australia
were extracted from a published paper [3]. We alsoextracted data on the age-specific incidence of reported
ESKD from tables in the 2011 USRDS annual report [14]
and the 2011 ERA-EDTA annual report [15].
Data analyses
Age- and gender-specific incidence rates were calculated
by dividing the number of incident patients for each age-
gender category by the total number of people in the
corresponding population. For comparisons with total in-
cidence rates of ESKD in Australia between 2003 and
2007, we calculated the incidence of RRT using data from
the JRDR during the same time period. We also calculated
the total incidence of paediatric ESKD using data from the
JSPN [11]. Standardised incidence ratios (SIRs) were cal-
culated by the indirect method, using age- and gender-
specific total incidence rates for Australia as the reference
category. Confidence intervals were determined assuming
that observed cases followed a Poisson distribution.
To compare incidence rates of the USRDS and the
ERA-EDTA, we calculated the incidence of RRT using
data from the JRDR in 2011. The incidence of RRT at
day 1 in the ERA-EDTA was used for this analysis. We
also compared the total incidence of paediatric ESKD
using data from the JSPN [11] for those aged <20 years
with the incidence of RRT reported by the USRDS and
the ERA-EDTA (Additional files 1, 2, and 3).
The current analyses used existing data without any
individual patient identifiers. The study was performed
according to the principles of the 2000 Declaration of
Helsinki as well as the Declaration of Istanbul 2008,
Japanese privacy protection laws, and ethical guidelines
for epidemiological studies published by the Ministry of
Education, Science and Culture, and the Ministry of
Health, Labour and Welfare in 2005.
Results and discussion
Age-specific incidence rates of RRT in Japan
There were 110,475 male and 62,217 female incident
cases of RRT in 2003–2007 in Japan. Unadjusted overall
incidence rates were 358.8 per million population (pmp)
(95 % confidence interval (CI), 356.7–360.9) for males
and 192.7 pmp (95 % CI, 191.2–194.2) for females
(Table 1). Age-specific incidence rates increased with
age, peaking between ages 80 and 84 years in both gen-
ders. The rates were higher in males than in females;
however, this gender difference was not apparent among
those aged <15 years.
Using data from the JSPN [11], there were no gen-
der differences in the total incidence of paediatric
ESKD among children aged <10 years (Additional file 1).
Age-specific total incidence rates of paediatric ESKD
were higher than the incidence rates of RRT shown in
Table 1 for all age groups, except among those aged
15–19 years.




Incident case Populationa Incidenceb (95 % CI) Incident case Populationa Incidenceb (95 % CI)
0–4 43 14,249,165 3.0 (2.2–4.1) 37 13,551,230 2.7 (1.9–3.8)
5–9 26 15,075,316 1.7 (1.1–2.5) 18 14,344,246 1.3 (0.7–2.0)
10–14 41 15,361,059 2.7 (1.9–3.6) 38 14,614,548 2.6 (1.8–3.6)
15–19 128 16,778,802 7.6 (6.4–9.1) 81 15,900,857 5.1 (4.0–6.3)
20–24 355 18,747,907 18.9 (17.0–21.0) 180 17,744,081 10.1 (8.7–11.7)
25–29 681 20,839,834 32.7 (30.3–35.2) 406 20,057,000 20.2 (18.3–22.3)
30–34 1385 23,994,021 57.7 (54.7–60.8) 724 23,324,334 31.0 (28.8–33.4)
35–39 2176 22,100,968 98.5 (94.4–102.7) 1047 21,607,875 48.5 (45.6–51.5)
40–44 3037 19,854,793 153.0 (147.6–158.5) 1449 19,519,867 74.2 (70.5–78.2)
45–49 4734 19,295,649 245.3 (234.8–252.4) 2238 19,150,550 116.9 (112.1–121.8)
50–54 8350 22,042,543 378.8 (370.7–387.0) 3961 22,159,275 178.8 (173.2–184.4)
55–59 12,972 24,739,582 524.3 (515.4–533.4) 5644 25,291,277 223.2 (217.4–229.1)
60–64 13,990 20,366,525 686.9 (675.6–698.4) 6617 21,542,247 307.2 (299.8–314.7)
65–69 16,000 17,861,105 895.8 (882.0–909.8) 8213 19,630,862 418.4 (409.4–427.5)
70–74 17,680 15,166,918 1165.7 (1148.6–1183.0) 9341 17,928,932 521.0 (510.5–531.7)
75–79 15,252 11,193,826 1362.5 (1341.0–1384.3) 9867 14,967,274 659.2 (646.3–672.4)
80–84 9119 6,180,288 1475.5 (1445.4–1506.1) 7591 10,954,849 692.9 (677.4–708.7)
≥85 4506 4,061,592 1109.4 (1077.3–1142.3) 4765 10,559,705 451.2 (438.5–464.2)
Total 110,475 307,909,893 358.8 (356.7–360.9) 62,217 322,849,009 192.7 (191.2–194.2)
Only patients who initiated dialysis treatment were included
CI confidence interval
aFive-year population at risk
bPer million age-related population (pmarp)
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Table 2 shows SIRs of the incidence of RRT in Japan in
comparison with the total incidence of ESKD in Australia
in 2003–2007. Overall SIRs were 1.19 (95 % CI, 1.18–1.20)
for males and 0.68 (95 % CI, 0.68–0.69) for females. For
males, Japan had lower SIRs at age <30 years, higher SIRs
in age band 30–79, and then lower SIRs at age ≥80 years.
Among males aged 50 to 69 years, incidence rates of RRT
in Japan were about twice as high as the total incidence of
ESKD among males in Australia. For females, Japan had
lower SIRs at age <35 years, higher SIRs in age band 40–
74, and then lower SIRs at age ≥75 years. Among females
aged 50 to 69 years, incidence rates of RRT in Japan were
about one and a half times higher than the total incidence
of ESKD among females in Australia.
When comparing the total incidence of paediatric
ESKD in Japan and Australia, Japan had lower SIRs at all
age groups except the female group aged 0–4 years and
the male group aged 10–14 years (Additional file 2).
Figure 1 shows age- and gender-specific incidence
rates of adult RRT in Japan in comparison with those of
the USRDS. The incidence increased with age, peaking
between ages 80 and 84 years in both countries, with
similar rates observed between Japanese males and theUSRDS. Japanese males have also substantially higher
rates compared with the ERA-EDTA (Fig. 2). Figure 3
shows the age- and gender-specific paediatric incidence
of RRT reported by the USRDS, the ERA-EDTA, and
the JRDR. Japan has lower incidence rates compared
with those reported by the USRDS and the ERA-EDTA.
Similar results were obtained using data from the JSPN
(Additional file 3).
Discussion
This study revealed that the incidence of RRT in middle-
aged individuals in Japan was almost twice the total inci-
dence of ESKD in Australia. Since data from Australia
included both treated and untreated ESKD [3], the
higher incidence in Japan cannot be explained by differ-
ences in the acceptance rate for RRT. Furthermore,
compared with the incidence rates of RRT reported by
the USRDS and the ERA-EDTA, Japanese males have
similar or substantially higher rates, respectively. These
findings suggest that there still is room for substantially
decreasing gender- and age-specific incidence rates of
ESKD in these populations.
The most striking finding of this study was that the in-
cidence of RRT in middle-aged individuals in Japan was




Incidence (95 % CI)a Expected cases SIR (95 % CI) Incidence (95 % CI)a Expected cases SIR (95 % CI)
0–4 0.8 (0.5–1.1) 114 0.38 (0.27–0.51) 0.3 (0.2–0.6) 41 0.91 (0.64–1.24)
5–9 0.8 (0.5–1.1) 121 0.22 (0.14–0.32) 0.6 (0.4–1.0) 86 0.21 (0.12–0.33)
10–14 0.5 (0.3–0.8) 77 0.53 (0.38–0.72) 0.8 (0.5–1.1) 117 0.33 (0.23–0.45)
15–19 1.6 (1.3–2.1) 268 0.48 (0.40–0.57) 1.3 (1.0–1.7) 207 0.39 (0.31–0.49)
20–24 2.7 (2.2–3.3) 506 0.70 (0.63–0.78) 1.8 (1.4–2.3) 319 0.56 (0.49–0.65)
25–29 4.0 (3.4–4.7) 834 0.82 (0.76–0.88) 3.0 (2.5–3.6) 602 0.67 (0.61–0.74)
30–34 4.8 (4.1–5.6) 1152 1.20 (1.14–1.27) 4.0 (3.4–4.7) 933 0.78 (0.72–0.84)
35–39 7.4 (6.5–8.3) 1635 1.33 (1.28–1.39) 5.0 (4.3–5.7) 1080 0.97 (0.91–1.03)
40–44 10.4 (9.4–11.5) 2065 1.47 (1.42–1.52) 6.8 (6.0–7.7) 1327 1.09 (1.04–1.15)
45–49 13.7 (12.5–15.0) 2644 1.79 (1.74–1.84) 8.7 (7.9–9.8) 1666 1.34 (1.29–1.40)
50–54 18.5 (17.0–20.1) 4078 2.05 (2.00–2.09) 10.8 (9.7–12.0) 2393 1.66 (1.60–1.71)
55–59 23.6 (21.9–25.5) 5839 2.22 (2.18–2.26) 16.3 (14.8–17.8) 4122 1.37 (1.33–1.41)
60–64 32.1 (29.8–34.7) 6538 2.14 (2.10–2.18) 21.2 (19.4–23.3) 4567 1.45 (1.41–1.48)
65–69 49.8 (46.4–53.4) 8895 1.80 (1.77–1.83) 33.7 (31.1–36.6) 6616 1.24 (1.22–1.27)
70–74 80.6 (75.8–85.8) 12,225 1.45 (1.43–4.70) 50.1 (46.6–53.9) 8982 1.04 (1.02–1.06)
75–79 127.5 (120.6–134.9) 14,272 1.07 (1.05–1.09) 75.8 (71.1–80.8) 11,345 0.87 (0.85–0.89)
80–84 216.1 (204.7–228.1) 13,356 0.68 (0.67–0.70) 117.5 (110.8–124.7) 12,872 0.59 (0.58–0.60)
≥85 447.3 (524.7–570.0) 18,168 0.25 (0.24–0.26) 318.7 (305.3–332.8) 33,654 0.14 (0.14–0.15)
Total 26.1 (22.5–30.0) 92,784 1.19 (1.18–1.20) 17.0 (14.9–19.2) 90,930 0.68 (0.68–0.69)
Reproduced from [3]
CI confidence interval, ESKD end-stage kidney disease, SIR standardised incidence ratio
aPer 100,000 population
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Although no data are available on the precise number of
untreated ESKD patients in Japan, the total incidence of
ESKD in Japan, including both treated and untreated pa-
tients, would be over twofold that reported in Australia.Fig. 1 Age- and gender-specific adult incidence rates of reported ESKD in
of Dialysis Therapy registry (JRDR) include data only for patients who undePrimary renal disease in new patients was similar be-
tween Australia and Japan. Specifically, diabetic nephropa-
thy was the most common cause of ESKD followed by
glomerulonephritis in both countries, although the pro-
portions were slightly different. Diabetic nephropathyJapan compared with the USRDS. Note: Data from the Japanese Society
rwent dialysis treatment
Fig. 2 Age- and gender-specific adult incidence rates of reported
ESKD in Japan compared with the ERA-EDTA. Note: Data from the
Japanese Society of Dialysis Therapy registry (JRDR) include data only
for patients who underwent dialysis treatment
Fig. 3 Paediatric incidence rates of reported ESKD in Japan compared
with the USRDS and the ERA-EDTA. Note: Data from the Japanese
Society of Dialysis Therapy registry (JRDR) include data only for patients
who underwent dialysis treatment
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41.0 % in Japan, respectively, in 2003, 30 and 41.0 % in
2004, 31 and 40.7 % in 2005, 32 and 36.6 % in 2006, and
31 and 43.5 % in 2007 [4–8, 16, 17]. Glomerulonephritis
and chronic glomerulonephritis were the second leading
cause in Australia and Japan, respectively. In Australia,
glomerulonephritis accounted for 27 % of new patients in
2003, 25 % in 2004, 24 % in 2005, 23 % in 2006, and 25 %
in 2007 [16, 17]. In Japan, chronic glomerulonephritis
accounted for 29.1 % in 2003, 28.1 % in 2004, 30.8 % in
2005, 23.7 % in 2006, and 23.8 % in 2007 [4–8]. Due to
differences in categories of underlying diseases by different
registries, direct comparisons may not be possible. Fur-
thermore, age- and sex-stratified data of primary renal dis-
ease are lacking. Given substantial differences in primary
renal diseases by age, this is an important area that re-
quires further research.
The timing of dialysis initiation was also similar between
Australia and Japan. The median estimated glomerular fil-
tration rate (eGFR) at RRT initiation in Australia was
around 6 to 7 mL/min/1.73 m2 between 2004 and 2007
[18]. On the other hand, the mean eGFR at dialysis initi-
ation in Japan was 6.52 mL/min/1.73 m2 in 2007 [19].
Thus, it is unlikely that Japanese patients begin dialysis at
a higher eGFR than patients in Australia.
One possibility is that the estimated total incidence of
ESKD in Australia is underestimated. Indeed, a recent re-
port regarding the quality of coding of ESKD in Australian
death records suggests that death records significantly
underestimate the impact of ESKD [20]. Thus, those who
die of ESKD without RRT in Australia may be underesti-
mated, and the acceptance rate of RRT in Australia may
be lower than the estimated rate. Notwithstanding, the
twofold increase in rates appears too large to be entirely
explained by the acceptance rate of RRT.
We cannot provide a conclusive explanation as to why
Japan has higher incidence rates of RRT; however, racial
differences may also play a role. A prospective cohort
study from the UK revealed that Indo-Asian people had
a higher incidence of ESKD than their Caucasian counter-
parts [21]. Another cohort study from the Netherlands re-
vealed that South-Asian patients with type 2 diabetes,
which is now the most common single cause of ESKD in
Japan, had a higher incidence and faster progression of
renal dysfunction compared with Dutch-European dia-
betic patients [22]. These studies suggest that the kidneys
of Asians may be more vulnerable than those of other eth-
nic groups.
The prevalence of chronic kidney disease (CKD) stages
3 and 4 in Japan is similar to that in the USA although
the general Japanese population seems to adopt a healthier
lifestyle, further supporting the notion that the kidneys of
Japanese people are more vulnerable. For example, the
distribution of healthy lifestyle scores, which reflects
Wakasugi et al. Renal Replacement Therapy  (2016) 2:5 Page 6 of 7adherence to five lifestyle factors (non-smoking, optimal
weight, moderate alcohol intake, regular physical activity,
and better eating patterns), was as follows among females
aged 34 to 59 years in the USA [23] and the general
Japanese population aged 40 to 74 years [24]: 4.2 and
0.5 %, respectively, had a score of 0 (least healthy); 21 and
5.2 % had a score of 1; 34 and 17.5 % had a score of 2; 27
and 31.3 % had a score of 3; 12 and 32.3 % had a score of
4; and 2.4 and 13.3 % had a score of 5 (most healthy), al-
though the definition of a healthy lifestyle slightly differed
between the studies. Nevertheless, the prevalence of CKD
stages 3 and 4 in Japan is similar to that in the USA
[25, 26]. Furthermore, the prevalence of proteinuria
in Japan is reportedly much higher than that in the
USA [27]. While these all support the notion that in-
cidence rates of ESKD can be attributed to racial dif-
ferences, factors other than race may also affect the
rates, since age-specific incidence rates of ESKD differ
substantially between the USRDS, the ERA-EDTA, and
Australia. Gathering and analysing more information on
these international differences will provide better insight
and help decrease the incidence of ESKD. To allow for
international comparisons in the future, data for all ESKD
registries should be reported in the same manner.
This study also revealed that the incidence of RRT in
men is higher than that in women in Japan. The reason
underlying this difference is unclear, as evidence for sex
differences in the incidence of RRT is scarce. Although
there are no apparent differences in the prevalence of
CKD stages 3–5 between Japanese men and women, the
prevalence of proteinuria, hypertension, and diabetes in
men are all higher than in women in the general Japanese
population [26], suggesting that men might be more likely
to progress to ESKD than women. Although access to dia-
lysis or patient/doctor preferences may also contribute to
these differences, no such data are available in Japan.
Thus, the reasons underlying the sex differences should be
addressed in future studies.
With respect to the young population, Japan has a
lower incidence of paediatric ESKD compared to the in-
cidence of ESKD reported by the USRDS and the ERA-
EDTA. Compared with the total incidence of ESKD in
Australia, Japan had lower SIRs in all age groups, except
the female group aged 0–4 years and the male group
aged 10–14 years. Although data available in the present
study do not provide sufficient information regarding
why Japan has such lower incidence rates of paediatric
ESKD, there are several potential explanations. First, uni-
versal screening with the urine dip-stick test, which was
introduced as an annual urinalysis screening programme
for every school child since 1973 in Japan, may have been
effective in preventing ESKD in children, whereas no glo-
bal consensus exists on whether screening for CKD
should be undertaken in children and adolescents andwhether such screening is cost effective [28]. Although
direct evidence is lacking, early referral and interven-
tion for glomerulonephritis identified by the screening
programme may have reduced the incidence of child-
hood ESKD in Japan [27]. Second, the incidence rates
of paediatric ESKD might be underestimated, particu-
larly in the group aged 15–19 years. The total inci-
dence rates of paediatric ESKD, which included patients
who did not initiate RRT or who received preemptive kid-
ney transplants, were lower than the rates of RRT in the
group aged 15–19 years, suggesting that the number of
paediatric ESKD patients may be much higher than
reported.
Despite the fact that Japan has one of the highest inci-
dence rates of ESKD among adults, it was previously re-
ported to be much lower than that in other high-income
countries [29]. Our findings, however, suggest that it
may premature to conclude that Japan has a lower inci-
dence of paediatric ESKD compared to other countries
without a more accurate survey of paediatric ESKD pa-
tients in Japan.
One strength of this study is that data were extracted
from a nationwide survey of Japanese dialysis facilities
and a national census. Thus, the findings should be
broadly generalisable to the Japanese population. En-
hanced awareness of these issues would enable nephrol-
ogists and healthcare professionals to advocate for the
need to prevent the development and progression of
CKD. However, our findings should be interpreted in the
context of the limitation inherent to this type of study,
i.e. only patients who underwent dialysis treatment were
included, as data were unavailable for patients who did
not initiate dialysis or who underwent preemptive kid-
ney transplantation in Japan. However, the number of
preemptive kidney transplant patients is small in Japan,
with only 101 patients being reported in 2009 [10]. In
addition, each registry uses different methods to collect
and report data. This could have introduced bias. Fur-
thermore, age- and sex-stratified data of comorbidities
or primary renal disease are limited due to the data
source. Given that these differ substantially by age and
sex, this is an important area that requires further
research.
Conclusions
Japan has a higher incidence of RRT among the middle-
aged and older-aged populations compared to the total
incidence rates of ESKD in Australia. Since data from
Australia included both treated and untreated ESKD
[3], the higher incidence in Japan cannot be explained
by differences in the acceptance rate for RRT. Thus, a
strategy targeting middle- and older-aged groups will
be necessary to decrease the incidence of ESKD in
Japan.
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